Vaccines against enteric infections: cholera, typhoid and shigellosis

Nitin K. Shah
PD Hinduja National Hospital, India

Typhoid vaccines: High disease burden of 21.6 million cases with 216,000 deaths, mounting drug resistance and difficulty in improving sanitation and safe drinking water make effective typhoid vaccines the only option in achieving immediate and effective control of typhoid fever in developing countries and for travelers to such countries.

**Typhoid vaccines:** Currently two typhoid vaccines are licensed for use i.e. Vi antigen injectable vaccine and oral Ty21a vaccine.

**Vi antigen typhoid vaccine:** Purified Vi antigen vaccine was developed by NIH, USA and is now licensed for persons > 2 years of age in more than 88 low and middle income countries.

**Safety:** Pooled estimates from trials done using Vi typhoid vaccine show that 1% of vaccinees develop fever and 3-4% develop swelling. Overall the side effects are mild and well tolerated.

**Efficacy:** Vi vaccines have been used in single dose given intramuscularly in 3 major field trials. Efficacy in these studies has been 72% (95% CI 41-87) at 17 mo follow up in Nepal, 55% (95% CI 30-71) at 3 year follow up in South Africa and 69% (95% CI 34-67) with liquid formulation in Indonesia. Meta-analysis of Ty21a vaccine studies estimates efficacy of 47% (95% CI 33-58) for enteric capsule formulation and 74% (95% CI 38-89) for liquid formulation. Recent data suggests that Ty21a vaccine is significantly protective even against paratyphi A (Chile) and paratyphi B (Israel).

**Vi conjugate vaccines:** Vi-rEPA conjugate vaccine was studied in 2-5 year old children in Vietnam given as 2 doses at 6 weeks interval. The efficacy at 27 months of active surveillance was 91.5% (95% CI 77.1-96.6) and 82.4% (95% CI 22.3-99.1) at 46 months.

**Newer typhoid vaccines:** Newer live attenuated typhoid vaccines are being evolved like CVD908, CVD 909, Ty800, ZH9 etc, including new Vi conjugate vaccines like Vi-CRM and Vi-DT vaccines.

Cholera vaccines: High disease burden of 3-5 million cases and 100,000-130,000 deaths, emergence of more virulent O1 El tor variant, increasing drug resistance and difficulty in improving sanitation and safe drinkable water make cholera vaccines desirable for control of cholera.

**Cholera vaccines:** Only 2 cholera vaccines are at present available for use. They include oral monovalent whole cell killed cholera vaccine with recombinant cholera toxin subunit B (WC-rBS - Dukoral) and oral and oral bivalent killed cholera vaccine without B subunit of cholera toxin (Shanchol/mOCCRVAX).

**WC-rBS (Dukoral):** This vaccine developed and licensed in Sweden in 1991 and is now licensed in more than 90 countries. It contains formalin and heat killed whole cells of O1 strain of cholera (both classic and El tor and Inaba and Ogawa) plus recombinant B subunit of cholera toxin. It is not licensed for < 2 years old.
Safety: The vaccine is very safe and side effects are mild GI disturbance. In a trial involving 240,000 participants the side effects in vaccinees were no more than in controls.

Efficacy: Trial done in Matlab, Bangladesh in 2-15 year old children and women > 16 years of age showed efficacy of 85% at 4-6 months, 62% during 1st year, 58% at during 2nd year which fell to 18% during 3rd year with overall efficacy of 51% over 3 years of follow up. Efficacy in 2-5 years old was 100% at 4-6 months, 38% in 1st year, 47% in 2nd year and 0% in 3rd year. Subsequent studies in Peru showed 86% protection against El tor cholera in 16-45 years old military recruits. Later case control trial done in Mozambique showed effectiveness at 1-6 months following vaccination with 2 doses and 78% with one or two doses. It also shows cross protection of 67% against ETEC diarrhea and 86% against severe ETEC diarrhea.

Shanchol/mORCVAX: Bivalent oral vaccine containing heat and formalin killed whole cells of O1 and O 139 strains of cholera without cholera B subunit are developed by International Vaccine Institute (IVI) with funding from Gates foundation and are now available as Shanchol in India and mORCVAX in Vietnam.

Efficacy: The new bivalent vaccine has been studied in a placebo controlled trial involving 100 adults and 100 children in Kolkata, India. The results of the study showed that the vaccine was safe and immunogenic in vaccinees with 53% of adult vaccinees and 80% of children 1-5 years old showing seroconversion to O1 strain. A double blind placebo controlled cluster study is ongoing in Kolkata, India using Shanchol involving 107774 subjects > 1 year old. Interim analysis showed effectiveness of 67% at 2 years follow up. The study will continue for 5 years.

Herd effect with cholera vaccines: Reanalysis of WC and WC-rBS vaccines studies done in Bangladesh showed herd effect seen with both the vaccines. It is estimated that at 50% coverage of the population the vaccine is likely to result in 93% reduction in cholera cases due to direct and herd effects of the vaccine.

Shigella vaccines: High disease burden of 90 million episodes with 500,000 deaths, emerging drug resistance coupled with difficulties in improving the standards of hygiene make Shigella vaccine the only alternative to control Shigella disease burden. Many vaccines have reached advanced stage of development, yet ideal Shigella vaccine is still eluding mankind.

Shigella vaccines: Except for a Chinese vaccine, no other Shigella vaccine is at present commercially available. Conjugate Shigella vaccines, live attenuated Shigella vaccines and invasion complex Shigella vaccines (Invaplex) are in various stages of development.

Live invasive Shigella vaccines: Currently Center for Vaccine Development (CVD) at University of Maryland, USA and Walter Reed Army Institute of Research (WRAIR), USA are perusing these vaccines. CVD 1204 vaccine contains guaBA mutation, CVD 1205 has guaBA and virG mutations and CVD 1207/1208 has guaBA, virG, and set and sen mutations. Comparative trial of CVD 1204 and 1208 using 3 doses of either vaccine in human volunteers showed that both the vaccines were highly immunogenic. Further field trials with CVD 1208 will confirm safety and immunogenicity and CVD is working on similar vaccines using other Shigella serotypes. SC 602 vaccine using S. flexneri 2a strain with mutation of virG gene was found to be safe and immunogenic in adult volunteers in USA. However subsequent study done in Bangladesh failed to show immunogenicity. This proves that one needs different dose of vaccine in endemic areas as compared to naïve population. Similar virG mutation based S. sonnei vaccine WRSS1 and S. dysenteriae 1 vaccines WRSd1 are being developed.

Conjugate Shigella vaccines: O-SP antigen has been conjugated to rEPA or CRM9 carriers. An earlier double blind vaccine controlled randomized study tested S. sonnei-rePA conjugate vaccine containing 25 µg of O-specific polysaccharide showed efficacy of 47% (28-100) against S. sonnei infection. A recent study used S. sonnei and S. flexneri vaccines conjugated with rEPA in 1-4 years old Israeli children. Efficacy was found to be 71% in 3-4 years old children. Further studies need to be conducted before this vaccine can be considered for commercial use.

Shigella invasin complex (Invaplex) vaccines: This vaccine developed by WRAIR contains LPS and invasive plasmid antigens Ipa B, IpaD and Ipa C and is called Invaplex 50. Phase 1 study done in human volunteers used Invalex-50 as 3 doses given intranasally divided between two nostrils at 0, 14, 28 days. Vaccine was found to be safe and immunogenic. Further studies are planned using this vaccine in field.

References
The Gram positive pathogen *Streptococcus pneumoniae*, (the pneumococcus), has contributed to our understanding of fundamental biology through the demonstration by Avery and co-workers more than 80 years ago, of DNA as the basis of the transforming principle of pneumococcal capsules, and therefore as the basis of heredity[1]. The pneumococcus has become the leading vaccine preventable cause of death and a successful and diverse human pathogen. More recently, the development of pneumococcal conjugate vaccine (PCV) has made possible the prevention of pneumococcal disease in infants, but also elucidated aspects of pneumococcal biology by the use of the vaccine as a probe to understand the burden of pneumococcal disease in children globally[2]; as infant mortality increases, the contribution of pneumonia and therefore of the pneumococcus to that mortality also increases[3, 4]. There is therefore significant optimism that the recent rollout of PCV under an advance market commitment will make a significant impact on the achievement of the millennium goal to reduce infant mortality by 2/3 by the year 2015.

Of particular interest is the impact of PCV on carriage as the vaccine has led to significant herd immunity in the US where is has reduced vaccine type invasive pneumococcal disease by more than 90% in adults through immunization of infants[5] Indeed 95% of the non-bacteremic pneumonia disease burden prevented in the USA by the immunization of infants has been seen in adults as the total burden of pneumonia in developed countries falls disproportionally on adults[6]. Immunization of infants has been shown to protect HIV infected adults from invasive disease due to the vaccine serotypes[7] although direct immunization of HIV infected adults with two doses of PCV has recently been demonstrated to be effective[8].

The impact of replacement on the reductions in disease burden post PCV introduction is the subject of much debate, but there is some consensus that the replacing strains tend to be less virulent, but are still able to cause a significant burden of disease in immunocompromised hosts.